Professor Robert Newton, PhD, AEP, CSCS*D, FESSA, FNSCA
Professor Robert Newton is Professor of Exercise Medicine in the Exercise Medicine Research Institute that he established (2004) at Edith Cowan University, Perth, Western Australia. Prior to appointment at Edith Cowan University, Professor Newton was Director of the Biomechanics Laboratory, at Ball State University in Indiana. He has also worked at the Pennsylvania State University as a visiting research fellow in the Center for Sports Medicine. Current major research directions include: exercise medicine as neoadjuvant, adjuvant and rehabilitative cancer therapy to reduce side-effects and enhance effectiveness of surgery, chemotherapy and radiation therapy; the influence of targeted exercise medicine on tumour biology and exercise medicine for reducing decline in quality of life, strength, body composition and functional ability in cancer patients.
Professor Newton is an Accredited Exercise Physiologist, Certified Strength and Conditioning Specialist with Distinction with the NSCA, Fellow of Exercise and Sports Science Australia and Fellow of the National Strength and Conditioning Association (NSCA), Member of the American Society of Clinical Oncology and American College of Sports Medicine. In 2004 he was awarded Outstanding Sports Scientist of the Year by the NSCA. In 2018 he received the career achievement award from the Cancer Council WA and was a finalist for Western Australian of the Year and finalist for the Premier’s Science Award. In 2019, Professor Newton was named the Western Australia Premier’s Scientist of the Year.
Professor Newton has published over 800 scientific papers including 400 refereed scientific journal articles, 450 conference abstracts and papers, three books, 16 book chapters and has a current Scopus h-Index of 76 with his work being cited over 19,500 times. Topic of greatest publication output is exercise and cancer for a field-weighted citation impact of 3.00 and prominence percentile of 99.31. As of 2020 Professor Newton had attracted over $36 Million in competitive research funding.